TREATMENT OF MITOCHONDRIAL DISEASES WITH SGC STIMULATORS
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various mitochondri...
Saved in:
Main Authors | , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
25.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various mitochondrial diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3 ',5 '-monophosphate (cGMP) or both, or an upregulation of the NO-sGC-cGMP pathway is desirable. Compounds useful in the methods of the invention are those of Formula I or pharmaceutically acceptable salts thereof.
La présente divulgation concerne l'utilisation de stimulateurs de guanylate cyclase soluble (sGC), des sels pharmaceutiquement acceptables de ceux-ci et des formulations pharmaceutiques ou des formes posologiques les comprenant, seuls ou en association avec un ou plusieurs agents supplémentaires, pour le traitement de diverses maladies mitochondriales, une augmentation de la stimulation de la sGC, une augmentation de la concentration en oxyde nitrique (NO) ou de guanosine 3', 5'-monophosphate (cGMP) cyclique ou des deux ou une régulation à la hausse de la voie NO-sGC-cGMP étant souhaitable. Les composés utiles dans les procédés de la divulgation sont ceux de Formule I ou des sels pharmaceutiquement acceptables de ceux-ci. |
---|---|
Bibliography: | Application Number: WO2023US35346 |